{"gene":"FGF2","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2018,"finding":"Crystal structure of the API5-FGF2 complex was determined, revealing critical residues driving the protein interaction. The structure provided a structural basis for the nuclear localization of the FGF2 isoform lacking a canonical nuclear localization signal and identified a cryptic nuclear localization sequence in FGF2. The API5-FGF2 interaction regulates mRNA nuclear export through both the TREX and eIF4E/LRPPRC mRNA export complexes.","method":"X-ray crystallography, Co-IP, mRNA export functional assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure solved with functional validation of interaction residues and mRNA export phenotype, single lab with multiple orthogonal methods","pmids":["32383752"],"is_preprint":false},{"year":2018,"finding":"FGF2 undergoes unconventional secretion by direct membrane translocation at the plasma membrane. Live-cell TIRF microscopy directly visualized individual FGF2 membrane translocation events with an average duration of ~200 ms. FGF2 forms oligomers (predominantly dimers) at the inner plasma membrane leaflet; these oligomers form membrane pores that serve as dynamic translocation intermediates. The process requires PI(4,5)P2-mediated recruitment at the inner leaflet and heparan sulfates capturing FGF2 at the outer leaflet.","method":"Live-cell TIRF microscopy, simultaneous dual-channel imaging, fluorescence-based oligomer detection","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct real-time visualization of translocation events with kinetic measurements, PI(4,5)P2 and heparan sulfate dependence established, mechanistic model supported by multiple orthogonal imaging approaches","pmids":["30470711"],"is_preprint":false},{"year":2022,"finding":"Cholesterol promotes clustering of PI(4,5)P2 at the plasma membrane, thereby enhancing FGF2 binding and oligomerization at the inner leaflet and facilitating FGF2 membrane translocation during unconventional secretion. Mechanistically, cholesterol increases PI(4,5)P2 head group visibility, induces PI(4,5)P2 clustering that drives FGF2 oligomerization, and increases membrane tension to facilitate lipidic pore formation.","method":"Live-cell imaging, atomistic molecular dynamics simulations, membrane tension experiments, lipid bilayer binding assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods including MD simulations, biophysical experiments, and live-cell assays converging on the same mechanistic conclusion","pmids":["36173379"],"is_preprint":false},{"year":2009,"finding":"High molecular weight (HMW) FGF2 isoforms are retained in the nucleus and act independently of FGF receptors (FGFR), in contrast to the 18 kDa secreted isoform that signals through cell-surface FGFR tyrosine kinases. HMW FGF2 undergoes distinct intracellular trafficking and has nuclear functions.","method":"Review synthesizing cell fractionation, isoform-specific expression, and nuclear localization studies","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — synthesis of multiple experimental observations from multiple labs; review article but grounded in documented experimental evidence","pmids":["18850066"],"is_preprint":false},{"year":2011,"finding":"FGF2 binds directly to Chlamydia trachomatis elementary bodies (EBs) and functions as a bridging molecule to facilitate EB interaction with FGFR on the host cell surface. Upon EB binding, FGFR is locally activated and contributes to bacterial uptake into non-phagocytic cells. C. trachomatis infection stimulates fgf2 transcription and enhances FGF2 production/release through a pathway requiring bacterial protein synthesis and Erk1/2 activation but independent of FGFR activation.","method":"Direct binding assays, FGFR activation assays, siRNA knockdown, pharmacological inhibition of FGFR and Erk1/2","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (binding assays, functional infection assays, pathway inhibitors), single lab","pmids":["21998584"],"is_preprint":false},{"year":2014,"finding":"Nuclear FGFR1 and FGF2 co-localize in the nucleus of activated pancreatic stellate cells (PSCs) at the invasive front of pancreatic cancer. Abrogation of nuclear FGF2 and FGFR1 in PSCs (via FGFR inhibition or RNAi) abolished cancer cell invasion in organotypic co-cultures, demonstrating that nuclear FGF2/FGFR1 signaling in PSCs drives invasion.","method":"IHC localization, RNAi, chemical FGFR inhibition, organotypic co-culture invasion assays","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — nuclear localization tied directly to invasion phenotype using loss-of-function with two orthogonal methods (RNAi and chemical inhibitor), single lab","pmids":["24503018"],"is_preprint":false},{"year":2019,"finding":"FGF2 signals through FGFR1/2 on bone marrow stromal cells to regulate secretion of FGF2-containing exosomes. These exosomes are endocytosed by leukemia cells and protect them from tyrosine kinase inhibitors. FGFR inhibition or Fgf2 gene silencing in stromal cells significantly decreased exosome secretion and reduced stromal protection of leukemia cells.","method":"Exosome isolation and characterization, Co-IP, FGFR inhibition/siRNA knockdown, Fgf2-/- mouse transplant model, TKI resistance assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo evidence, multiple methods including genetic knockout mouse model and pharmacological inhibition, single lab","pmids":["30720426"],"is_preprint":false},{"year":2009,"finding":"FGF2 activates ERK MAP kinase, which phosphorylates Runx2 at Ser-301, leading to increased Runx2 acetylation, decreased ubiquitination, and protein stabilization. This ERK-mediated post-translational modification of Runx2 underlies FGF2-stimulated osteoblast differentiation.","method":"Western blotting, site-directed mutagenesis (Ser-301), constitutively active MEK overexpression, ERK inhibitor treatment, in silico analysis of ERK phosphorylation sites","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis identifying the critical phosphorylation residue combined with multiple biochemical assays (phosphorylation, acetylation, ubiquitination, protein level), single lab but multiple orthogonal methods","pmids":["20007706"],"is_preprint":false},{"year":2013,"finding":"FGF2 stimulates osteogenic differentiation by inducing TAZ expression via ERK activation. FGF2 increases TAZ mRNA expression and promotes nuclear localization of TAZ, facilitating TAZ-Runx2 interaction and Runx2-mediated gene transcription. Depletion of TAZ via shRNA blocked FGF2-mediated osteogenic differentiation.","method":"shRNA knockdown, ERK inhibition, nuclear fractionation, Co-IP of TAZ-Runx2, gene expression analysis","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (shRNA) with specific phenotypic readout (osteogenesis), TAZ-Runx2 interaction confirmed by Co-IP, ERK pathway confirmed by inhibition, single lab","pmids":["24125755"],"is_preprint":false},{"year":2007,"finding":"FGF2 triggers transcriptional upregulation of PDGFR-alpha and -beta in endothelial cells, conferring hyperresponsiveness to PDGF-BB. Reciprocally, PDGF-BB upregulates FGFR1 promoter activity in vascular smooth muscle cells, making them responsive to FGF2. This reciprocal interaction promotes disorganized neovascularization and tumor metastasis.","method":"Promoter activity assays, receptor expression analysis, tumor co-overexpression models in mice, in vivo angiogenesis and metastasis assays","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter activity assays and in vivo tumor models with receptor expression analysis, multiple methods, single lab","pmids":["17909625"],"is_preprint":false},{"year":2019,"finding":"FGF2 regulates pathologic choroidal neovascularization via STAT3 activation. In ex vivo choroidal sprouting and in vivo CNV models, FGF2 was identified as the essential FGF ligand for FGFR1/2-dependent angiogenesis, acting through STAT3 pathway activation.","method":"Ex vivo choroidal sprouting assay, in vivo CNV mouse model, STAT3 pathway inhibition","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and ex vivo models with pathway-specific inhibition, single lab","pmids":["31449793"],"is_preprint":false},{"year":2011,"finding":"CCN2 (connective tissue growth factor) directly binds to FGF2 via its C-terminal (CT) module with a dissociation constant of 5.5 nM as measured by surface plasmon resonance. This interaction nullifies FGF2-induced chondrocyte proliferation and MMP9/MMP13 production. The CT module decreased ERK1/2, p38 MAPK, and JNK phosphorylation induced by FGF2. Separately, full-length CCN2 (not CT alone) also binds FGF receptor 1 (Kd ~362 nM).","method":"Solid-phase binding assay, Co-IP/Western blot, surface plasmon resonance (SPR), cell proliferation assay, phosphorylation analysis","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding quantified by SPR (Kd determination), confirmed by Co-IP, functional consequences measured by signaling and proliferation assays, single lab with multiple orthogonal methods","pmids":["21914781"],"is_preprint":false},{"year":2015,"finding":"PLAP-1/Asporin directly binds FGF2 and promotes formation of the FGF2-FGFR1 complex, positively regulating FGF2 activity. Plap-1-/- mouse embryonic fibroblasts showed defective responses to FGF2, which were rescued by Plap-1 transfection. Immunocytochemistry showed reduced FGF2-FGFR1 co-localization in Plap-1-/- MEFs.","method":"Binding assays, genetic knockout (Plap-1-/- mice), transfection rescue, immunocytochemistry","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding confirmed, genetic knockout with rescue experiment, colocalization imaging, single lab","pmids":["26239644"],"is_preprint":false},{"year":2023,"finding":"VEGF-B binds to FGFR1 and induces FGFR1/VEGFR1 complex formation, suppressing FGF2-induced ERK activation and FGF2-driven angiogenesis and tumor growth. VEGF-B functions as an endogenous inhibitor of the FGF2/FGFR1 pathway when FGFR1 is abundantly expressed.","method":"Binding assays, receptor co-immunoprecipitation (FGFR1/VEGFR1 complex), ERK phosphorylation assays, in vitro and in vivo angiogenesis models","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor complex formation confirmed by Co-IP, functional inhibition of ERK and angiogenesis demonstrated in vitro and in vivo, single lab with multiple orthogonal methods","pmids":["37591843"],"is_preprint":false},{"year":2006,"finding":"Heparanase (HPSE) modulates FGF2 binding and signaling in melanoma cells by remodeling heparan sulfate (HS) proteoglycans. Low HPSE concentrations enhanced FGF2 binding and enabled ERK and FAK phosphorylation in response to FGF2 (which was absent without HPSE treatment). Higher HPSE concentrations inhibited FGF2 binding. Soluble HPSE-degraded HS enhanced FGF2-induced ERK but not FAK phosphorylation, demonstrating differential modulation of FGF2 downstream signals.","method":"FGF2 binding assays, ERK/FAK phosphorylation assays, angiogenesis assays, HPSE dose-response experiments","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding and signaling assays with dose-response, functional angiogenesis outcomes, single lab","pmids":["16867222"],"is_preprint":false},{"year":2014,"finding":"FGF2 promotes resistance to imatinib in CML via the FGF receptor 3/RAS/c-RAF/MAPK pathway. FGF2 was uniquely capable of promoting growth in short- and long-term resistance assays, and this resistance could be overcome with ponatinib, a multikinase inhibitor targeting BCR-ABL and FGFR.","method":"In vitro growth/resistance assays, pathway inhibitor experiments, clinical patient bone marrow immunohistochemistry, pharmacological reversal","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro pathway identification combined with clinical correlate evidence, single lab","pmids":["24408322"],"is_preprint":false},{"year":2014,"finding":"API5 mediates tumor immune escape by upregulating FGF2 signaling through a FGFR1/PKCδ/ERK effector pathway that triggers degradation of the pro-apoptotic molecule BIM. Blockade of FGF2, PKCδ, or ERK phenocopied API5 silencing in restoring immune sensitivity.","method":"RNAi silencing, pathway inhibitors (FGF2, PKCδ, ERK blockade), apoptosis assays with antigen-specific T cells","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific pathway phenocopying, multiple inhibitors targeting the same pathway, single lab","pmids":["24769442"],"is_preprint":false},{"year":2017,"finding":"FGF2 regulates cytoglobin (CYGB) gene expression and deactivation of myofibroblastic hepatic stellate cells (HSCs) via JNK signaling. FGF2 triggered rapid phosphorylation of JNK and c-JUN; chromatin immunoprecipitation showed phospho-c-JUN binds to the CYGB promoter at -218 to -222 bases from the transcription initiation site. JNK inhibition and c-JUN siRNA abrogated FGF2-mediated CYGB induction.","method":"Western blot (JNK/c-JUN phosphorylation), ChIP assay (phospho-c-JUN at CYGB promoter), siRNA knockdown, JNK inhibitor, in vivo bile duct ligation model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — ChIP identifying specific promoter binding site plus siRNA knockdown plus pharmacological inhibition plus in vivo validation, single lab with multiple orthogonal methods","pmids":["28916723"],"is_preprint":false},{"year":2010,"finding":"Protein kinase C-delta (PKCδ) physically interacts with connexin43 (Cx43) during FGF2 signaling in osteoblasts. PKCδ preferentially co-precipitates phosphorylated Cx43, and pull-down assays demonstrated that PKCδ associates with the C-terminal tail of Cx43. Cx43 serves as a direct docking platform for PKCδ recruitment to affect FGF2 signaling.","method":"Co-immunoprecipitation, pull-down assay with Cx43 C-terminal tail, immunofluorescent co-detection","journal":"BMC biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and pull-down confirming physical interaction, localization confirmed by immunofluorescence, single lab","pmids":["20338032"],"is_preprint":false},{"year":2019,"finding":"FGF2-induced ERK signaling dynamics in PC12 cells emerge through an intracellular feedback mechanism combined with competition of FGF2 binding to FGFRs and heparan sulfate proteoglycan (HSPG) co-receptors. This competition produces a distinct population-level distribution of transient/sustained ERK signaling states, revealed by temporally controlled microfluidic growth factor perturbations and Bayesian parameter inference.","method":"Microfluidics-based temporal perturbation, live-cell ERK biosensor imaging, Bayesian parameter inference/model selection","journal":"Molecular systems biology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — quantitative temporal perturbations with live-cell imaging and computational model selection; mechanistic model of FGFR/HSPG competition confirmed, single lab","pmids":["31777174"],"is_preprint":false},{"year":2004,"finding":"FGF2 induces G1 cell cycle arrest in RCS chondrocytes through a Ras/ERK pathway-dependent mechanism. FGF2 activated PLCγ, PKB, ERK, and p38 MAPK. Chemical inhibition of FGFR3 or MEK1/2 antagonized FGF2-mediated growth arrest. Dominant-negative Ras partially reversed growth inhibition. At the molecular level, FGF2-induced arrest involved disintegration of cyclin D3-cdk6 complex and increased association of p21(WAF1) and p27(Kip1) with cyclin-cdk2 and cyclin-cdk4 complexes, inhibiting their kinase activities and leading to underphosphorylation of p107 and p130.","method":"Chemical inhibitors (FGFR3, MEK), dominant-negative Ras expression, cell cycle analysis, kinase complex immunoprecipitation, kinase activity assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple loss-of-function approaches and biochemical characterization of cyclin-CDK complexes, single lab with multiple orthogonal methods","pmids":["15194433"],"is_preprint":false},{"year":2014,"finding":"FGF2 activates TRPC channels in satellite cells, leading to increased intracellular calcium ([Ca2+]i). This calcium elevation induces nuclear translocation of NFATc3 and NFATc2, and increases the number of MyoD-positive cells. These effects were antagonized by the TRPC channel blocker SKF 96365, identifying a pathway: FGF2 → TRPC → [Ca2+]i elevation → NFAT nuclear translocation → MyoD expression/satellite cell activation.","method":"Immunostaining, live-cell calcium imaging with X-rhod-1 dye, TRPC blocker (SKF 96365), nuclear translocation imaging, MyoD counting","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct calcium imaging in satellite cells on fibers, pharmacological inhibition at multiple pathway steps, multiple readouts, single lab","pmids":["24575047"],"is_preprint":false},{"year":2018,"finding":"Translocated intracellular FGF2 (endocytosed from outside the cell) protects cells against apoptosis independently of FGFR activation and downstream signaling. This anti-apoptotic activity was abolished by inhibitors of FGF2 translocation from endosomes to the cell interior, but not by potent FGFR kinase inhibitors or kinase-dead FGFR1 mutants.","method":"FGFR inhibitor treatment, kinase-dead FGFR1 mutant expression, endosomal translocation inhibitors, apoptosis assays (serum starvation/staurosporine models)","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic separation of FGFR-dependent vs. translocation-dependent activities using multiple orthogonal inhibitors, single lab","pmids":["30099027"],"is_preprint":false},{"year":2009,"finding":"FGF2 stimulates SDF-1 expression in Sertoli cells via FGFR4-dependent upregulation of Erm transcription factor. Erm knockdown by siRNA decreased Sdf-1 levels. EMSA revealed ERM directly binds to a specific Ets binding site (-846 to -851 nt region) in the Sdf-1 promoter. FGFR4, expressed in TM4 Sertoli cells but not ST2 stromal cells, mediates the differential FGF2 response.","method":"siRNA knockdown, FGFR subtype analysis, FGFR blocking experiments, EMSA, Sdf-1 promoter activity assay","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA identifying specific DNA-binding site, siRNA knockdown, FGFR subtype specificity demonstrated, single lab with multiple methods","pmids":["19301256"],"is_preprint":false},{"year":2012,"finding":"HoxA10 directly transcriptionally activates the FGF2 gene in myeloid cells via two cis-elements in the proximal FGF2 promoter. HoxA10-driven FGF2 production induces a PI3K-dependent increase in β-catenin, causing autocrine stimulation of myeloid progenitor proliferation.","method":"Promoter reporter assays with cis-element identification, ChIP-type analysis, FGF2 ELISA, PI3K inhibitor, β-catenin western blotting, proliferation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cis-element identification in FGF2 promoter with functional pathway analysis, single lab with multiple methods","pmids":["22493287"],"is_preprint":false},{"year":2023,"finding":"YY1 lactylation at lysine 183 (K183), regulated by p300 acetyltransferase, directly enhances FGF2 transcription in microglia under hypoxia, promoting retinal neovascularization. YY1 K183 mutation eliminated the enhanced FGF2 transcription and angiogenic effects. p300 inhibitor A485 suppressed vascularization in vivo and in vitro.","method":"Lactylation site identification by mass spectrometry, site-directed mutagenesis (K183), p300 overexpression/inhibition (A485), FGF2 promoter activity assays, in vivo OIR model","journal":"Genome biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis of specific lactylation site with functional transcription readout, pharmacological validation in vivo, single lab","pmids":["37085894"],"is_preprint":false},{"year":2021,"finding":"ONECUT2 directly binds the FGF2 promoter and transcriptionally upregulates FGF2 expression in HCC. FGF2 in turn upregulates ONECUT2 through the FGFR1/ERK/ELK1 pathway, forming a positive feedback loop. FGF2 knockdown inhibited ONECUT2-mediated HCC metastasis.","method":"ChIP assay (ONECUT2 binding FGF2 promoter), siRNA/shRNA knockdown, FGFR1 inhibitor (PD173074), ERK pathway analysis, metastasis assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct promoter binding, pharmacological pathway inhibition, loss-of-function with metastasis phenotype, single lab","pmids":["34839358"],"is_preprint":false},{"year":2017,"finding":"FGF2 mutants with substitutions at Lys-119/Arg-120 and Lys-125 (K119E/R120E and K125E) in the predicted integrin αvβ3 binding interface show reduced integrin binding and are defective in ERK1/2 activation and DNA synthesis. These integrin-binding defective FGF2 mutants act as dominant-negative antagonists, suppressing FGF2 signaling, tube formation, aortic ring sprouting, and in vivo angiogenesis.","method":"Integrin binding assays, site-directed mutagenesis, ERK1/2 phosphorylation assays, DNA synthesis assay, tube formation, aortic ring assay, in vivo angiogenesis","journal":"Bioscience reports","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis identifying integrin-binding interface residues with functional validation in vitro and in vivo, single lab with multiple orthogonal assays","pmids":["28302677"],"is_preprint":false},{"year":2021,"finding":"FGF2 inhibits thermogenesis in brown and beige adipocytes via autocrine/paracrine mechanisms. Exogenous FGF2 suppresses PGC-1α and PPARγ expression, leading to UCP1 suppression in brown and beige adipocytes. Co-IP experiments and ChIP assays were used to elucidate the mechanism. FGF2-KO mice show enhanced UCP1 expression and thermogenic capacity.","method":"FGF2-KO mice, Co-IP, ChIP, luciferase reporter assay, FGF2 supplementation in vitro, FGFR inhibitor, PPARγ agonist, PGC-1α lentivirus","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO combined with in vitro mechanistic dissection using Co-IP, ChIP, and luciferase assays, single lab with multiple orthogonal methods","pmids":["34710640"],"is_preprint":false},{"year":2022,"finding":"FGF-2 signaling in nasopharyngeal carcinoma promotes pericyte-specific expression of CXCL14 via FGFR1/AHR signaling. Pericyte-derived CXCL14 recruits macrophages and promotes their polarization toward an M2-like phenotype. Genetic knockdown of FGF2 or pericyte depletion blocked CXCL14 expression and tumor-associated macrophage infiltration.","method":"Gain- and loss-of-function (FGF2 knockdown, pericyte depletion), FGFR1/AHR pathway analysis, xenograft mouse models","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown and cell-type depletion with in vivo validation, pathway mechanistically defined, single lab","pmids":["35439170"],"is_preprint":false},{"year":2020,"finding":"FGF2-induced tanycyte proliferation requires connexin 43 (Cx43) hemichannel opening and subsequent purinergic signaling. FGF2 exposure opens tanycytic Cx43 hemichannels, enabling ATP release to the extracellular milieu. Extracellular ATP activates P2Y1 receptors to drive cell division. In vivo continuous infusion of FGF2 with a Cx43 HC inhibitor into the third ventricle blocked β-tanycyte proliferation.","method":"BrdU incorporation, Cx43 HC inhibitors (in vitro and in vivo), P2Y1 receptor inhibitors, ATP release measurement, ICV infusion in rats","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition at multiple pathway steps in vitro and in vivo, BrdU functional readout, single lab","pmids":["32936929"],"is_preprint":false},{"year":2021,"finding":"YAP is translocated to the nucleus after radiation in glioma cells, where it promotes FGF2 expression and secretion. Secreted FGF2 then activates the MAPK-ERK pathway to promote DNA damage repair and radioresistance. FGF2 was identified as a novel direct transcriptional target gene of YAP.","method":"YAP nuclear translocation imaging, FGF2 promoter ChIP/reporter assays, pharmacological inhibition of YAP-FGF2-MAPK axis, intracranial xenograft models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — nuclear translocation documented, direct transcriptional target relationship established, signaling pathway validated with inhibitors in vitro and in vivo, single lab","pmids":["34127812"],"is_preprint":false},{"year":2009,"finding":"Endogenous FGF-2 is required for parathyroid hormone (PTH) anabolic effects on osteoblasts. PTH increased Runx-2 protein expression and nuclear accumulation, and phospho-CREB levels in Fgf2+/+ but not Fgf2-/- osteoblasts. FGF-2 silencing in Fgf2+/+ osteoblasts blocked PTH-stimulated Runx-2 and CREB phosphorylation. PTH increased cyclinD1-cdk4/6 in Fgf2+/+ but not Fgf2-/- osteoblasts.","method":"Fgf2-/- and Fgf2+/+ osteoblasts, FGF-2 siRNA silencing, Western blot for Runx-2/p-CREB/cyclin-CDK complexes, immunocytochemistry","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout and siRNA silencing with multiple downstream signaling readouts, single lab","pmids":["19107841"],"is_preprint":false}],"current_model":"FGF2 exists as multiple isoforms: an 18-kDa secreted form that signals through cell-surface FGFR tyrosine kinases (activating Ras/MAPK/ERK, PI3K, PLCγ, STAT3, and JNK pathways) and high molecular weight nuclear isoforms that act independently of FGFRs; the 18-kDa form is secreted by an unconventional, ER/Golgi-independent mechanism requiring PI(4,5)P2-driven oligomerization and membrane pore formation at the plasma membrane (enhanced by cholesterol-mediated PI(4,5)P2 clustering), with heparan sulfate proteoglycans capturing FGF2 extracellularly; intracellularly, translocated FGF2 exerts FGFR-independent anti-apoptotic activity, and nuclear FGF2 complexes with API5 to regulate mRNA export; FGF2 signaling controls diverse processes including osteoblast differentiation (via ERK-dependent Runx2 phosphorylation at Ser-301 and TAZ induction), satellite cell activation (via TRPC-Ca2+-NFAT), HSC deactivation (via JNK/c-JUN-dependent CYGB transcription), tanycyte proliferation (via Cx43 hemichannel/purinergic axis), and tumor angiogenesis (via STAT3 and reciprocal PDGFR/FGFR upregulation); its activity is modulated by extracellular interactors including heparan sulfate proteoglycans, heparanase, CCN2, PLAP-1/Asporin, and VEGF-B (which inhibits FGF2/FGFR1 signaling by inducing FGFR1/VEGFR1 complex formation)."},"narrative":{"mechanistic_narrative":"FGF2 is a multifunctional growth factor that exists as a secreted 18-kDa isoform signaling through cell-surface FGFR tyrosine kinases and high molecular weight nuclear isoforms that act independently of FGFRs [PMID:18850066]. The 18-kDa form reaches the extracellular space through an unconventional, ER/Golgi-independent route: it is recruited to the inner plasma membrane leaflet by PI(4,5)P2, oligomerizes (predominantly as dimers) into membrane-pore translocation intermediates directly visualized in real time, and is captured at the outer leaflet by heparan sulfates [PMID:30470711]; cholesterol promotes this secretion by clustering PI(4,5)P2 and raising membrane tension to favor pore formation [PMID:36173379]. Once engaged with FGFRs and heparan-sulfate co-receptors, FGF2 drives ERK/MAPK, PI3K, PLCγ, STAT3, and JNK outputs whose kinetics are shaped by competition between FGFR and heparan sulfate proteoglycan binding [PMID:31777174, PMID:15194433]. Through ERK, FGF2 governs osteoblast differentiation by phosphorylating Runx2 at Ser-301 to stabilize it and by inducing TAZ to promote TAZ-Runx2 transcription [PMID:20007706, PMID:24125755], and endogenous FGF2 is required for the PTH anabolic response in osteoblasts [PMID:19107841]; through other branches it controls satellite-cell activation via a TRPC-Ca2+-NFAT-MyoD axis [PMID:24575047], deactivates hepatic stellate cells by driving JNK/c-JUN-dependent CYGB transcription [PMID:28916723], and stimulates tanycyte proliferation via Cx43 hemichannel ATP release and purinergic P2Y1 signaling [PMID:32936929]. FGF2 is a central driver of pathologic angiogenesis and tumor progression, acting through STAT3, reciprocal PDGFR/FGFR cross-induction, and an integrin αvβ3-binding interface required for ERK activation and neovascularization [PMID:17909625, PMID:31449793, PMID:28302677]. Nuclear FGF2 complexes with API5 through a cryptic nuclear localization sequence to regulate mRNA export via the TREX and eIF4E/LRPPRC pathways [PMID:32383752], and intracellularly translocated FGF2 exerts FGFR-independent anti-apoptotic activity [PMID:30099027]. Its activity is tuned by extracellular interactors including heparanase-remodeled heparan sulfate [PMID:16867222], CCN2 [PMID:21914781], PLAP-1/Asporin [PMID:26239644], and VEGF-B, which inhibits FGF2/FGFR1 signaling by inducing FGFR1/VEGFR1 complexes [PMID:37591843].","teleology":[{"year":2004,"claim":"Established that FGF2 can act as a growth-arrest signal rather than only a mitogen, defining how it imposes G1 arrest through Ras/ERK in chondrocytes.","evidence":"Chemical inhibitors, dominant-negative Ras, and cyclin-CDK complex analysis in RCS chondrocytes","pmids":["15194433"],"confidence":"Medium","gaps":["Cell-type basis for arrest versus proliferation outputs not resolved","Did not address nuclear FGF2 isoform contributions"]},{"year":2009,"claim":"Resolved how FGF2-ERK signaling is converted into osteoblast differentiation by identifying Runx2 Ser-301 as the ERK phosphorylation site controlling Runx2 stability.","evidence":"Site-directed mutagenesis, constitutively active MEK, and ERK inhibition with biochemical readouts","pmids":["20007706"],"confidence":"High","gaps":["Kinase-substrate directness in vivo not shown","Other ERK substrates in osteogenesis not mapped"]},{"year":2009,"claim":"Distinguished FGFR-independent nuclear HMW FGF2 isoforms from the FGFR-signaling 18-kDa form, framing FGF2 as a dual intracellular/extracellular factor.","evidence":"Review synthesizing cell fractionation, isoform expression, and nuclear localization studies","pmids":["18850066"],"confidence":"Medium","gaps":["Molecular mechanism of HMW nuclear function unspecified","Trafficking determinants not defined"]},{"year":2009,"claim":"Showed endogenous FGF2 is necessary for the PTH anabolic program, placing FGF2 as a required cofactor in hormone-driven osteoblast signaling.","evidence":"Fgf2-/- versus Fgf2+/+ osteoblasts plus siRNA silencing with Runx2/CREB/cyclin-CDK readouts","pmids":["19107841"],"confidence":"Medium","gaps":["Whether intracrine or autocrine FGF2 mediates the requirement unresolved","Receptor subtype not defined"]},{"year":2013,"claim":"Added a transcriptional arm to FGF2-driven osteogenesis by showing ERK-induced TAZ enables TAZ-Runx2 cooperation.","evidence":"shRNA knockdown, ERK inhibition, nuclear fractionation, and TAZ-Runx2 Co-IP","pmids":["24125755"],"confidence":"Medium","gaps":["Mechanism linking ERK to TAZ induction not detailed","Single cell-system validation"]},{"year":2014,"claim":"Defined distinct effector branches downstream of FGF2 in non-bone tissues — TRPC-Ca2+-NFAT for satellite cell activation.","evidence":"Calcium imaging, TRPC blocker, and NFAT/MyoD readouts in satellite cells","pmids":["24575047"],"confidence":"Medium","gaps":["FGFR subtype coupling TRPC not identified","Direct channel activation mechanism not shown"]},{"year":2017,"claim":"Identified a JNK/c-JUN transcriptional output through which FGF2 deactivates myofibroblastic hepatic stellate cells by driving CYGB.","evidence":"ChIP localizing phospho-c-JUN to the CYGB promoter, siRNA, JNK inhibition, and in vivo bile duct ligation","pmids":["28916723"],"confidence":"High","gaps":["Upstream coupling from FGFR to JNK not mapped","Reversibility of HSC deactivation not addressed"]},{"year":2017,"claim":"Mapped an integrin αvβ3-binding interface on FGF2 required for ERK activation and angiogenesis, yielding dominant-negative antagonist mutants.","evidence":"Site-directed mutagenesis at Lys-119/Arg-120 and Lys-125 with binding, signaling, and in vivo angiogenesis assays","pmids":["28302677"],"confidence":"Medium","gaps":["Structural integrin-FGF2 complex not determined","Relationship to FGFR engagement not fully separated"]},{"year":2018,"claim":"Provided the structural basis for nuclear FGF2 by solving the API5-FGF2 complex and identifying a cryptic NLS, linking nuclear FGF2 to mRNA export.","evidence":"X-ray crystallography, Co-IP, and mRNA export functional assays implicating TREX and eIF4E/LRPPRC","pmids":["32383752"],"confidence":"High","gaps":["In vivo physiological role of API5-FGF2 mRNA export unclear","Isoform specificity of nuclear import not fully resolved"]},{"year":2018,"claim":"Directly visualized the unconventional secretion mechanism, showing FGF2 oligomerizes and forms membrane-pore translocation intermediates at the plasma membrane.","evidence":"Live-cell TIRF microscopy with dual-channel imaging and oligomer detection establishing PI(4,5)P2 and heparan sulfate dependence","pmids":["30470711"],"confidence":"High","gaps":["Pore stoichiometry and resealing dynamics not fully defined","In vivo relevance of measured kinetics unaddressed"]},{"year":2018,"claim":"Separated FGFR-independent intracellular function of FGF2 by showing translocated FGF2 protects against apoptosis independent of receptor kinase activity.","evidence":"FGFR kinase inhibitors, kinase-dead FGFR1, and endosomal translocation inhibitors in apoptosis assays","pmids":["30099027"],"confidence":"Medium","gaps":["Intracellular anti-apoptotic effector(s) unidentified","Mechanism of endosome-to-cytosol translocation incomplete"]},{"year":2019,"claim":"Quantitatively explained variability in FGF2-ERK signaling as a consequence of FGFR/HSPG co-receptor competition with intracellular feedback.","evidence":"Microfluidic temporal perturbations, live-cell ERK biosensors, and Bayesian model selection in PC12 cells","pmids":["31777174"],"confidence":"Medium","gaps":["Molecular identity of the intracellular feedback node not specified","Generalizability beyond PC12 cells untested"]},{"year":2022,"claim":"Explained how membrane lipid composition gates FGF2 secretion, showing cholesterol clusters PI(4,5)P2 to promote oligomerization and pore formation.","evidence":"Live-cell imaging, atomistic MD simulations, and membrane tension/binding assays","pmids":["36173379"],"confidence":"High","gaps":["Physiological regulation of cholesterol-driven secretion in vivo not shown","Quantitative contribution relative to PI(4,5)P2 alone not parsed"]},{"year":2023,"claim":"Identified VEGF-B as an endogenous inhibitor of FGF2/FGFR1 signaling acting by inducing FGFR1/VEGFR1 receptor complexes.","evidence":"Binding assays, receptor Co-IP, ERK phosphorylation, and in vitro/in vivo angiogenesis models","pmids":["37591843"],"confidence":"Medium","gaps":["Structural basis of the FGFR1/VEGFR1 complex not resolved","Context-dependence on FGFR1 abundance needs broader validation"]},{"year":null,"claim":"How the FGFR-dependent surface signaling, FGFR-independent intracellular protection, and nuclear mRNA-export functions of FGF2 are coordinated within a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated model linking isoform partitioning to functional output","Quantitative balance between unconventional secretion and intracrine retention unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[3,9,10,13]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,19,20]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[1,2]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,3,5]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,11]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,17,19,20]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,10,15,26,31]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[1,2]}],"complexes":["FGF2-API5 nuclear complex","FGF2-FGFR1 receptor complex"],"partners":["FGFR1","API5","CCN2","PLAP-1/ASPN","VEGFB","HEPARAN SULFATE PROTEOGLYCAN","INTEGRIN ALPHAVBETA3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09038","full_name":"Fibroblast growth factor 2","aliases":["Basic fibroblast growth factor","bFGF","Heparin-binding growth factor 2","HBGF-2"],"length_aa":288,"mass_kda":30.8,"function":"Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:8663044). Also acts as an integrin ligand which is required for FGF2 signaling (PubMed:28302677). Binds to integrin ITGAV:ITGB3 (PubMed:28302677). Plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration (PubMed:28302677, PubMed:8663044). Functions as a potent mitogen in vitro (PubMed:1721615, PubMed:3732516, PubMed:3964259). Can induce angiogenesis (PubMed:23469107, PubMed:28302677). Mediates phosphorylation of ERK1/2 and thereby promotes retinal lens fiber differentiation (PubMed:29501879)","subcellular_location":"Secreted; Nucleus","url":"https://www.uniprot.org/uniprotkb/P09038/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FGF2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FGF2","total_profiled":1310},"omim":[{"mim_id":"620882","title":"SECONDARY OSSIFICATION CENTER-ASSOCIATED REGULATOR OF CHONDROCYTE MATURATION; SNORC","url":"https://www.omim.org/entry/620882"},{"mim_id":"620879","title":"FIBROBLAST GROWTH FACTOR-BINDING PROTEIN 3; FGFBP3","url":"https://www.omim.org/entry/620879"},{"mim_id":"620088","title":"WWC2 ANTISENSE RNA 1, NONCODING; WWC2AS1","url":"https://www.omim.org/entry/620088"},{"mim_id":"617853","title":"SMALL VASOHIBIN-BINDING PROTEIN; SVBP","url":"https://www.omim.org/entry/617853"},{"mim_id":"617425","title":"IMMUNOSKELETAL DYSPLASIA WITH NEURODEVELOPMENTAL ABNORMALITIES; ISDNA","url":"https://www.omim.org/entry/617425"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FGF2"},"hgnc":{"alias_symbol":[],"prev_symbol":["FGFB"]},"alphafold":{"accession":"P09038","domains":[{"cath_id":"2.80.10.50","chopping":"173-286","consensus_level":"high","plddt":95.9934,"start":173,"end":286}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09038","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09038-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09038-F1-predicted_aligned_error_v6.png","plddt_mean":70.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FGF2","jax_strain_url":"https://www.jax.org/strain/search?query=FGF2"},"sequence":{"accession":"P09038","fasta_url":"https://rest.uniprot.org/uniprotkb/P09038.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09038/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09038"}},"corpus_meta":[{"pmid":"10864959","id":"PMC_10864959","title":"Basic fibroblast growth factor (Fgf2) is necessary for cell proliferation and neurogenesis in the developing cerebral cortex.","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10864959","citation_count":343,"is_preprint":false},{"pmid":"37085894","id":"PMC_37085894","title":"YY1 lactylation in microglia promotes angiogenesis through transcription activation-mediated upregulation of FGF2.","date":"2023","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/37085894","citation_count":252,"is_preprint":false},{"pmid":"15564063","id":"PMC_15564063","title":"Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage.","date":"2004","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/15564063","citation_count":244,"is_preprint":false},{"pmid":"17909625","id":"PMC_17909625","title":"Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17909625","citation_count":244,"is_preprint":false},{"pmid":"23352645","id":"PMC_23352645","title":"MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23352645","citation_count":161,"is_preprint":false},{"pmid":"27007053","id":"PMC_27007053","title":"Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27007053","citation_count":154,"is_preprint":false},{"pmid":"31421589","id":"PMC_31421589","title":"VEGF and FGF-2: Promising targets for the treatment of respiratory disorders.","date":"2019","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31421589","citation_count":144,"is_preprint":false},{"pmid":"27572168","id":"PMC_27572168","title":"MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2.","date":"2016","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/27572168","citation_count":130,"is_preprint":false},{"pmid":"24503018","id":"PMC_24503018","title":"Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion.","date":"2014","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24503018","citation_count":129,"is_preprint":false},{"pmid":"19439615","id":"PMC_19439615","title":"A new role for FGF2 as an endogenous inhibitor of anxiety.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19439615","citation_count":127,"is_preprint":false},{"pmid":"11245570","id":"PMC_11245570","title":"TGF beta 2, LIF and FGF2 cooperate to induce nephrogenesis.","date":"2001","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11245570","citation_count":127,"is_preprint":false},{"pmid":"19541589","id":"PMC_19541589","title":"Inflammatory cells and chemokines sustain FGF2-induced angiogenesis.","date":"2009","source":"European cytokine network","url":"https://pubmed.ncbi.nlm.nih.gov/19541589","citation_count":115,"is_preprint":false},{"pmid":"9373031","id":"PMC_9373031","title":"FGF-2 converts mature oligodendrocytes to a novel phenotype.","date":"1997","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/9373031","citation_count":109,"is_preprint":false},{"pmid":"20007706","id":"PMC_20007706","title":"FGF2-activated ERK mitogen-activated protein kinase enhances Runx2 acetylation and stabilization.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20007706","citation_count":109,"is_preprint":false},{"pmid":"27362808","id":"PMC_27362808","title":"miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27362808","citation_count":109,"is_preprint":false},{"pmid":"9537840","id":"PMC_9537840","title":"Regulation of astrocyte GFAP expression by TGF-beta1 and FGF-2.","date":"1998","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/9537840","citation_count":91,"is_preprint":false},{"pmid":"15765505","id":"PMC_15765505","title":"Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development.","date":"2005","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/15765505","citation_count":90,"is_preprint":false},{"pmid":"23437109","id":"PMC_23437109","title":"Sustained levels of FGF2 maintain undifferentiated stem cell cultures with biweekly feeding.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23437109","citation_count":87,"is_preprint":false},{"pmid":"17204151","id":"PMC_17204151","title":"VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis.","date":"2007","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/17204151","citation_count":78,"is_preprint":false},{"pmid":"16867222","id":"PMC_16867222","title":"FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells.","date":"2006","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16867222","citation_count":74,"is_preprint":false},{"pmid":"10411093","id":"PMC_10411093","title":"FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation.","date":"1999","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/10411093","citation_count":73,"is_preprint":false},{"pmid":"10767083","id":"PMC_10767083","title":"Programmed cell death in the developing heart: regulation by BMP4 and FGF2.","date":"2000","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/10767083","citation_count":70,"is_preprint":false},{"pmid":"25190353","id":"PMC_25190353","title":"MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2.","date":"2014","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25190353","citation_count":69,"is_preprint":false},{"pmid":"24125755","id":"PMC_24125755","title":"FGF2 stimulates osteogenic differentiation through ERK induced TAZ expression.","date":"2013","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/24125755","citation_count":67,"is_preprint":false},{"pmid":"16455048","id":"PMC_16455048","title":"Impaired bone anabolic response to parathyroid hormone in Fgf2-/- and Fgf2+/- mice.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16455048","citation_count":64,"is_preprint":false},{"pmid":"26816250","id":"PMC_26816250","title":"miR-105/Runx2 axis mediates FGF2-induced ADAMTS expression in osteoarthritis cartilage.","date":"2016","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/26816250","citation_count":63,"is_preprint":false},{"pmid":"35439170","id":"PMC_35439170","title":"FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35439170","citation_count":62,"is_preprint":false},{"pmid":"15194433","id":"PMC_15194433","title":"FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15194433","citation_count":62,"is_preprint":false},{"pmid":"15943814","id":"PMC_15943814","title":"FGF-2, IL-1beta and TGF-beta regulate fibroblast expression of S100A8.","date":"2005","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/15943814","citation_count":61,"is_preprint":false},{"pmid":"30720426","id":"PMC_30720426","title":"FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30720426","citation_count":58,"is_preprint":false},{"pmid":"18850066","id":"PMC_18850066","title":"High molecular weight FGF2: the biology of a nuclear growth factor.","date":"2009","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/18850066","citation_count":58,"is_preprint":false},{"pmid":"26650737","id":"PMC_26650737","title":"miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26650737","citation_count":58,"is_preprint":false},{"pmid":"37591843","id":"PMC_37591843","title":"VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37591843","citation_count":55,"is_preprint":false},{"pmid":"29681540","id":"PMC_29681540","title":"FGF2 Has Distinct Molecular Functions from GDNF in the Mouse Germline Niche.","date":"2018","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29681540","citation_count":54,"is_preprint":false},{"pmid":"19107841","id":"PMC_19107841","title":"Endogenous FGF-2 is critically important in PTH anabolic effects on bone.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19107841","citation_count":54,"is_preprint":false},{"pmid":"17656107","id":"PMC_17656107","title":"Creating a neurogenic environment: the role of BDNF and FGF2.","date":"2007","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/17656107","citation_count":53,"is_preprint":false},{"pmid":"21998584","id":"PMC_21998584","title":"Chlamydia trachomatis co-opts the FGF2 signaling pathway to enhance infection.","date":"2011","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/21998584","citation_count":51,"is_preprint":false},{"pmid":"21266348","id":"PMC_21266348","title":"HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21266348","citation_count":50,"is_preprint":false},{"pmid":"19264883","id":"PMC_19264883","title":"Retinal expression of Fgf2 in RCS rats with subretinal microphotodiode array.","date":"2009","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/19264883","citation_count":46,"is_preprint":false},{"pmid":"28302677","id":"PMC_28302677","title":"The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis.","date":"2017","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/28302677","citation_count":45,"is_preprint":false},{"pmid":"24769442","id":"PMC_24769442","title":"API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24769442","citation_count":45,"is_preprint":false},{"pmid":"29361536","id":"PMC_29361536","title":"FGF2-dependent mesenchyme and laminin-111 are niche factors in salivary gland organoids.","date":"2018","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/29361536","citation_count":44,"is_preprint":false},{"pmid":"34127812","id":"PMC_34127812","title":"Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34127812","citation_count":44,"is_preprint":false},{"pmid":"21914781","id":"PMC_21914781","title":"Effect of CCN2 on FGF2-induced proliferation and MMP9 and MMP13 productions by chondrocytes.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21914781","citation_count":44,"is_preprint":false},{"pmid":"24142921","id":"PMC_24142921","title":"Identification and characterization of FGF2-dependent mRNA: microRNA networks during lens fiber cell differentiation.","date":"2013","source":"G3 (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/24142921","citation_count":42,"is_preprint":false},{"pmid":"34839358","id":"PMC_34839358","title":"ONECUT2 facilitates hepatocellular carcinoma metastasis by transcriptionally upregulating FGF2 and ACLY.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34839358","citation_count":42,"is_preprint":false},{"pmid":"24408322","id":"PMC_24408322","title":"Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24408322","citation_count":42,"is_preprint":false},{"pmid":"24186558","id":"PMC_24186558","title":"Cooperative effects of FGF-2 and VEGF-A in periodontal ligament cells.","date":"2013","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/24186558","citation_count":40,"is_preprint":false},{"pmid":"28916723","id":"PMC_28916723","title":"Fibroblast growth factor 2 (FGF2) regulates cytoglobin expression and activation of human hepatic stellate cells via JNK signaling.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28916723","citation_count":40,"is_preprint":false},{"pmid":"25790378","id":"PMC_25790378","title":"Biphasic effects of FGF2 on adipogenesis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25790378","citation_count":39,"is_preprint":false},{"pmid":"13130507","id":"PMC_13130507","title":"Expression of CD137 and its ligand in human neurons, astrocytes, and microglia: modulation by FGF-2.","date":"2003","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/13130507","citation_count":39,"is_preprint":false},{"pmid":"33154173","id":"PMC_33154173","title":"FGF2 and IL-1β - explorers of unconventional secretory pathways at a glance.","date":"2020","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/33154173","citation_count":38,"is_preprint":false},{"pmid":"1894478","id":"PMC_1894478","title":"Basic fibroblast growth factor (FGFb) and epidermal growth factor (EGF) receptor messenger RNA production in human lacrimal gland.","date":"1991","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/1894478","citation_count":38,"is_preprint":false},{"pmid":"18055262","id":"PMC_18055262","title":"FGF2 in asthmatic airway-smooth-muscle-cell hyperplasia.","date":"2007","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18055262","citation_count":37,"is_preprint":false},{"pmid":"24490960","id":"PMC_24490960","title":"Malondialdehyde mediates oxidized LDL-induced coronary toxicity through the Akt-FGF2 pathway via DNA methylation.","date":"2014","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/24490960","citation_count":37,"is_preprint":false},{"pmid":"33434172","id":"PMC_33434172","title":"FGF2/FGFR signaling promotes cumulus-oocyte complex maturation in vitro.","date":"2021","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33434172","citation_count":36,"is_preprint":false},{"pmid":"28765647","id":"PMC_28765647","title":"FGF2 cooperates with IL-17 to promote autoimmune inflammation.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28765647","citation_count":36,"is_preprint":false},{"pmid":"22493287","id":"PMC_22493287","title":"HoxA10 protein regulates transcription of gene encoding fibroblast growth factor 2 (FGF2) in myeloid cells.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22493287","citation_count":36,"is_preprint":false},{"pmid":"18202785","id":"PMC_18202785","title":"Expression analysis of VEGFA, FGF2, TGFbeta1, EGF and IGF1 in human nasal polyposis.","date":"2008","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/18202785","citation_count":36,"is_preprint":false},{"pmid":"23684572","id":"PMC_23684572","title":"FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination.","date":"2013","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/23684572","citation_count":36,"is_preprint":false},{"pmid":"32383752","id":"PMC_32383752","title":"Regulation of mRNA export through API5 and nuclear FGF2 interaction.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/32383752","citation_count":35,"is_preprint":false},{"pmid":"31449793","id":"PMC_31449793","title":"FGF2-induced STAT3 activation regulates pathologic neovascularization.","date":"2019","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/31449793","citation_count":35,"is_preprint":false},{"pmid":"30470711","id":"PMC_30470711","title":"Single event visualization of unconventional secretion of FGF2.","date":"2018","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30470711","citation_count":35,"is_preprint":false},{"pmid":"31777174","id":"PMC_31777174","title":"Temporal perturbation of ERK dynamics reveals network architecture of FGF2/MAPK signaling.","date":"2019","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/31777174","citation_count":34,"is_preprint":false},{"pmid":"20338032","id":"PMC_20338032","title":"Interaction of connexin43 and protein kinase C-delta during FGF2 signaling.","date":"2010","source":"BMC biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20338032","citation_count":33,"is_preprint":false},{"pmid":"30013642","id":"PMC_30013642","title":"FGF2 and FGFR2 in patients with idiopathic pulmonary fibrosis and lung cancer.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30013642","citation_count":32,"is_preprint":false},{"pmid":"25701259","id":"PMC_25701259","title":"FGF2 Prevents Sunitinib-Induced Cardiotoxicity in Zebrafish and Cardiomyoblast H9c2 Cells.","date":"2016","source":"Cardiovascular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/25701259","citation_count":32,"is_preprint":false},{"pmid":"34203430","id":"PMC_34203430","title":"Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34203430","citation_count":31,"is_preprint":false},{"pmid":"27976512","id":"PMC_27976512","title":"FGF2 antagonizes aberrant TGFβ regulation of tropomyosin: role for posterior capsule opacity.","date":"2016","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27976512","citation_count":31,"is_preprint":false},{"pmid":"11745459","id":"PMC_11745459","title":"FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11745459","citation_count":31,"is_preprint":false},{"pmid":"24575047","id":"PMC_24575047","title":"FGF2 activates TRPC and Ca(2+) signaling leading to satellite cell activation.","date":"2014","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24575047","citation_count":31,"is_preprint":false},{"pmid":"29215722","id":"PMC_29215722","title":"FGF-2 promotes osteocyte differentiation through increased E11/podoplanin expression.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29215722","citation_count":30,"is_preprint":false},{"pmid":"32174197","id":"PMC_32174197","title":"FGF2: a novel druggable target for glioblastoma?","date":"2020","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/32174197","citation_count":28,"is_preprint":false},{"pmid":"19482688","id":"PMC_19482688","title":"The role of FGF-2 in renal fibrogenesis.","date":"2009","source":"Frontiers in bioscience (Scholar edition)","url":"https://pubmed.ncbi.nlm.nih.gov/19482688","citation_count":28,"is_preprint":false},{"pmid":"35784556","id":"PMC_35784556","title":"FGF2 Is Protective Towards Cisplatin-Induced KGN Cell Toxicity by Promoting FTO Expression and Autophagy.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35784556","citation_count":27,"is_preprint":false},{"pmid":"31130839","id":"PMC_31130839","title":"Effects of FGF2/FGFR1 Pathway on Expression of A1 Astrocytes After Infrasound Exposure.","date":"2019","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31130839","citation_count":27,"is_preprint":false},{"pmid":"30099027","id":"PMC_30099027","title":"Translocation of Exogenous FGF1 and FGF2 Protects the Cell against Apoptosis Independently of Receptor Activation.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30099027","citation_count":27,"is_preprint":false},{"pmid":"20432442","id":"PMC_20432442","title":"Signaling pathways implicated in PGF2alpha effects on Fgf2+/+ and Fgf2-/- osteoblasts.","date":"2010","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20432442","citation_count":27,"is_preprint":false},{"pmid":"19014962","id":"PMC_19014962","title":"Neonatal FGF2 alters cocaine self-administration in the adult rat.","date":"2008","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/19014962","citation_count":27,"is_preprint":false},{"pmid":"19301256","id":"PMC_19301256","title":"FGF2 stimulates SDF-1 expression through the Erm transcription factor in Sertoli cells.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19301256","citation_count":27,"is_preprint":false},{"pmid":"23625726","id":"PMC_23625726","title":"Up-regulated cten by FGF2 contributes to FGF2-mediated cell migration.","date":"2013","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23625726","citation_count":26,"is_preprint":false},{"pmid":"32936929","id":"PMC_32936929","title":"The FGF2-induced tanycyte proliferation involves a connexin 43 hemichannel/purinergic-dependent pathway.","date":"2020","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32936929","citation_count":25,"is_preprint":false},{"pmid":"26239644","id":"PMC_26239644","title":"PLAP-1/Asporin Positively Regulates FGF-2 Activity.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/26239644","citation_count":23,"is_preprint":false},{"pmid":"30629183","id":"PMC_30629183","title":"Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth.","date":"2019","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30629183","citation_count":23,"is_preprint":false},{"pmid":"33676544","id":"PMC_33676544","title":"Effect of fibronectin, FGF-2, and BMP4 in the stemness maintenance of BMSCs and the metabolic and proteomic cues involved.","date":"2021","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33676544","citation_count":23,"is_preprint":false},{"pmid":"30005872","id":"PMC_30005872","title":"The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30005872","citation_count":22,"is_preprint":false},{"pmid":"15725477","id":"PMC_15725477","title":"Coexpression and regulation of the FGF-2 and FGF antisense genes in leukemic cells.","date":"2004","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/15725477","citation_count":22,"is_preprint":false},{"pmid":"17029006","id":"PMC_17029006","title":"Modulation of antigenic phenotype in cultured human osteoblast-like cells by FGFb, TGFbeta1, PDGF-BB, IL-2, IL-1beta, LPS and IFNgamma.","date":"2006","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/17029006","citation_count":22,"is_preprint":false},{"pmid":"27608170","id":"PMC_27608170","title":"Stage-specific roles of FGF2 signaling in human neural development.","date":"2016","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27608170","citation_count":21,"is_preprint":false},{"pmid":"33206726","id":"PMC_33206726","title":"TGF-β-induced activation of conjunctival fibroblasts is modulated by FGF-2 and substratum stiffness.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/33206726","citation_count":21,"is_preprint":false},{"pmid":"34710640","id":"PMC_34710640","title":"FGF2 disruption enhances thermogenesis in brown and beige fat to protect against adiposity and hepatic steatosis.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34710640","citation_count":20,"is_preprint":false},{"pmid":"33162101","id":"PMC_33162101","title":"NEAT1 Knockdown Inhibits Keloid Fibroblast Progression by miR-196b-5p/FGF2 Axis.","date":"2020","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/33162101","citation_count":20,"is_preprint":false},{"pmid":"29649366","id":"PMC_29649366","title":"FGF2 Enhances Odontoblast Differentiation by αSMA+ Progenitors In Vivo.","date":"2018","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/29649366","citation_count":20,"is_preprint":false},{"pmid":"19768790","id":"PMC_19768790","title":"Influence of FGF2 and PEG hydrogel matrix properties on hMSC viability and spreading.","date":"2010","source":"Journal of biomedical materials research. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19768790","citation_count":20,"is_preprint":false},{"pmid":"39214017","id":"PMC_39214017","title":"Dihydroartemisinin inhibited vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway.","date":"2024","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39214017","citation_count":19,"is_preprint":false},{"pmid":"29364044","id":"PMC_29364044","title":"Linc-RAM is required for FGF2 function in regulating myogenic cell differentiation.","date":"2018","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/29364044","citation_count":19,"is_preprint":false},{"pmid":"11025644","id":"PMC_11025644","title":"Particle irradiation induces FGF2 expression in normal human lens cells.","date":"2000","source":"Radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/11025644","citation_count":19,"is_preprint":false},{"pmid":"26403263","id":"PMC_26403263","title":"FGF2 Overrides TGFβ1-Driven Integrin ITGA11 Expression in Human Dermal Fibroblasts.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26403263","citation_count":18,"is_preprint":false},{"pmid":"36173379","id":"PMC_36173379","title":"Cholesterol promotes clustering of PI(4,5)P2 driving unconventional secretion of FGF2.","date":"2022","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36173379","citation_count":17,"is_preprint":false},{"pmid":"29956066","id":"PMC_29956066","title":"Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer.","date":"2018","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29956066","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51386,"output_tokens":9292,"usd":0.146769,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19258,"output_tokens":4691,"usd":0.106783,"stage2_stop_reason":"end_turn"},"total_usd":0.253552,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structure of the API5-FGF2 complex was determined, revealing critical residues driving the protein interaction. The structure provided a structural basis for the nuclear localization of the FGF2 isoform lacking a canonical nuclear localization signal and identified a cryptic nuclear localization sequence in FGF2. The API5-FGF2 interaction regulates mRNA nuclear export through both the TREX and eIF4E/LRPPRC mRNA export complexes.\",\n      \"method\": \"X-ray crystallography, Co-IP, mRNA export functional assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure solved with functional validation of interaction residues and mRNA export phenotype, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32383752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FGF2 undergoes unconventional secretion by direct membrane translocation at the plasma membrane. Live-cell TIRF microscopy directly visualized individual FGF2 membrane translocation events with an average duration of ~200 ms. FGF2 forms oligomers (predominantly dimers) at the inner plasma membrane leaflet; these oligomers form membrane pores that serve as dynamic translocation intermediates. The process requires PI(4,5)P2-mediated recruitment at the inner leaflet and heparan sulfates capturing FGF2 at the outer leaflet.\",\n      \"method\": \"Live-cell TIRF microscopy, simultaneous dual-channel imaging, fluorescence-based oligomer detection\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct real-time visualization of translocation events with kinetic measurements, PI(4,5)P2 and heparan sulfate dependence established, mechanistic model supported by multiple orthogonal imaging approaches\",\n      \"pmids\": [\"30470711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cholesterol promotes clustering of PI(4,5)P2 at the plasma membrane, thereby enhancing FGF2 binding and oligomerization at the inner leaflet and facilitating FGF2 membrane translocation during unconventional secretion. Mechanistically, cholesterol increases PI(4,5)P2 head group visibility, induces PI(4,5)P2 clustering that drives FGF2 oligomerization, and increases membrane tension to facilitate lipidic pore formation.\",\n      \"method\": \"Live-cell imaging, atomistic molecular dynamics simulations, membrane tension experiments, lipid bilayer binding assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods including MD simulations, biophysical experiments, and live-cell assays converging on the same mechanistic conclusion\",\n      \"pmids\": [\"36173379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"High molecular weight (HMW) FGF2 isoforms are retained in the nucleus and act independently of FGF receptors (FGFR), in contrast to the 18 kDa secreted isoform that signals through cell-surface FGFR tyrosine kinases. HMW FGF2 undergoes distinct intracellular trafficking and has nuclear functions.\",\n      \"method\": \"Review synthesizing cell fractionation, isoform-specific expression, and nuclear localization studies\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — synthesis of multiple experimental observations from multiple labs; review article but grounded in documented experimental evidence\",\n      \"pmids\": [\"18850066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FGF2 binds directly to Chlamydia trachomatis elementary bodies (EBs) and functions as a bridging molecule to facilitate EB interaction with FGFR on the host cell surface. Upon EB binding, FGFR is locally activated and contributes to bacterial uptake into non-phagocytic cells. C. trachomatis infection stimulates fgf2 transcription and enhances FGF2 production/release through a pathway requiring bacterial protein synthesis and Erk1/2 activation but independent of FGFR activation.\",\n      \"method\": \"Direct binding assays, FGFR activation assays, siRNA knockdown, pharmacological inhibition of FGFR and Erk1/2\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (binding assays, functional infection assays, pathway inhibitors), single lab\",\n      \"pmids\": [\"21998584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Nuclear FGFR1 and FGF2 co-localize in the nucleus of activated pancreatic stellate cells (PSCs) at the invasive front of pancreatic cancer. Abrogation of nuclear FGF2 and FGFR1 in PSCs (via FGFR inhibition or RNAi) abolished cancer cell invasion in organotypic co-cultures, demonstrating that nuclear FGF2/FGFR1 signaling in PSCs drives invasion.\",\n      \"method\": \"IHC localization, RNAi, chemical FGFR inhibition, organotypic co-culture invasion assays\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — nuclear localization tied directly to invasion phenotype using loss-of-function with two orthogonal methods (RNAi and chemical inhibitor), single lab\",\n      \"pmids\": [\"24503018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF2 signals through FGFR1/2 on bone marrow stromal cells to regulate secretion of FGF2-containing exosomes. These exosomes are endocytosed by leukemia cells and protect them from tyrosine kinase inhibitors. FGFR inhibition or Fgf2 gene silencing in stromal cells significantly decreased exosome secretion and reduced stromal protection of leukemia cells.\",\n      \"method\": \"Exosome isolation and characterization, Co-IP, FGFR inhibition/siRNA knockdown, Fgf2-/- mouse transplant model, TKI resistance assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo evidence, multiple methods including genetic knockout mouse model and pharmacological inhibition, single lab\",\n      \"pmids\": [\"30720426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FGF2 activates ERK MAP kinase, which phosphorylates Runx2 at Ser-301, leading to increased Runx2 acetylation, decreased ubiquitination, and protein stabilization. This ERK-mediated post-translational modification of Runx2 underlies FGF2-stimulated osteoblast differentiation.\",\n      \"method\": \"Western blotting, site-directed mutagenesis (Ser-301), constitutively active MEK overexpression, ERK inhibitor treatment, in silico analysis of ERK phosphorylation sites\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis identifying the critical phosphorylation residue combined with multiple biochemical assays (phosphorylation, acetylation, ubiquitination, protein level), single lab but multiple orthogonal methods\",\n      \"pmids\": [\"20007706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FGF2 stimulates osteogenic differentiation by inducing TAZ expression via ERK activation. FGF2 increases TAZ mRNA expression and promotes nuclear localization of TAZ, facilitating TAZ-Runx2 interaction and Runx2-mediated gene transcription. Depletion of TAZ via shRNA blocked FGF2-mediated osteogenic differentiation.\",\n      \"method\": \"shRNA knockdown, ERK inhibition, nuclear fractionation, Co-IP of TAZ-Runx2, gene expression analysis\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (shRNA) with specific phenotypic readout (osteogenesis), TAZ-Runx2 interaction confirmed by Co-IP, ERK pathway confirmed by inhibition, single lab\",\n      \"pmids\": [\"24125755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FGF2 triggers transcriptional upregulation of PDGFR-alpha and -beta in endothelial cells, conferring hyperresponsiveness to PDGF-BB. Reciprocally, PDGF-BB upregulates FGFR1 promoter activity in vascular smooth muscle cells, making them responsive to FGF2. This reciprocal interaction promotes disorganized neovascularization and tumor metastasis.\",\n      \"method\": \"Promoter activity assays, receptor expression analysis, tumor co-overexpression models in mice, in vivo angiogenesis and metastasis assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter activity assays and in vivo tumor models with receptor expression analysis, multiple methods, single lab\",\n      \"pmids\": [\"17909625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF2 regulates pathologic choroidal neovascularization via STAT3 activation. In ex vivo choroidal sprouting and in vivo CNV models, FGF2 was identified as the essential FGF ligand for FGFR1/2-dependent angiogenesis, acting through STAT3 pathway activation.\",\n      \"method\": \"Ex vivo choroidal sprouting assay, in vivo CNV mouse model, STAT3 pathway inhibition\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and ex vivo models with pathway-specific inhibition, single lab\",\n      \"pmids\": [\"31449793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCN2 (connective tissue growth factor) directly binds to FGF2 via its C-terminal (CT) module with a dissociation constant of 5.5 nM as measured by surface plasmon resonance. This interaction nullifies FGF2-induced chondrocyte proliferation and MMP9/MMP13 production. The CT module decreased ERK1/2, p38 MAPK, and JNK phosphorylation induced by FGF2. Separately, full-length CCN2 (not CT alone) also binds FGF receptor 1 (Kd ~362 nM).\",\n      \"method\": \"Solid-phase binding assay, Co-IP/Western blot, surface plasmon resonance (SPR), cell proliferation assay, phosphorylation analysis\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding quantified by SPR (Kd determination), confirmed by Co-IP, functional consequences measured by signaling and proliferation assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21914781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PLAP-1/Asporin directly binds FGF2 and promotes formation of the FGF2-FGFR1 complex, positively regulating FGF2 activity. Plap-1-/- mouse embryonic fibroblasts showed defective responses to FGF2, which were rescued by Plap-1 transfection. Immunocytochemistry showed reduced FGF2-FGFR1 co-localization in Plap-1-/- MEFs.\",\n      \"method\": \"Binding assays, genetic knockout (Plap-1-/- mice), transfection rescue, immunocytochemistry\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding confirmed, genetic knockout with rescue experiment, colocalization imaging, single lab\",\n      \"pmids\": [\"26239644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"VEGF-B binds to FGFR1 and induces FGFR1/VEGFR1 complex formation, suppressing FGF2-induced ERK activation and FGF2-driven angiogenesis and tumor growth. VEGF-B functions as an endogenous inhibitor of the FGF2/FGFR1 pathway when FGFR1 is abundantly expressed.\",\n      \"method\": \"Binding assays, receptor co-immunoprecipitation (FGFR1/VEGFR1 complex), ERK phosphorylation assays, in vitro and in vivo angiogenesis models\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor complex formation confirmed by Co-IP, functional inhibition of ERK and angiogenesis demonstrated in vitro and in vivo, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"37591843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Heparanase (HPSE) modulates FGF2 binding and signaling in melanoma cells by remodeling heparan sulfate (HS) proteoglycans. Low HPSE concentrations enhanced FGF2 binding and enabled ERK and FAK phosphorylation in response to FGF2 (which was absent without HPSE treatment). Higher HPSE concentrations inhibited FGF2 binding. Soluble HPSE-degraded HS enhanced FGF2-induced ERK but not FAK phosphorylation, demonstrating differential modulation of FGF2 downstream signals.\",\n      \"method\": \"FGF2 binding assays, ERK/FAK phosphorylation assays, angiogenesis assays, HPSE dose-response experiments\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding and signaling assays with dose-response, functional angiogenesis outcomes, single lab\",\n      \"pmids\": [\"16867222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FGF2 promotes resistance to imatinib in CML via the FGF receptor 3/RAS/c-RAF/MAPK pathway. FGF2 was uniquely capable of promoting growth in short- and long-term resistance assays, and this resistance could be overcome with ponatinib, a multikinase inhibitor targeting BCR-ABL and FGFR.\",\n      \"method\": \"In vitro growth/resistance assays, pathway inhibitor experiments, clinical patient bone marrow immunohistochemistry, pharmacological reversal\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro pathway identification combined with clinical correlate evidence, single lab\",\n      \"pmids\": [\"24408322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"API5 mediates tumor immune escape by upregulating FGF2 signaling through a FGFR1/PKCδ/ERK effector pathway that triggers degradation of the pro-apoptotic molecule BIM. Blockade of FGF2, PKCδ, or ERK phenocopied API5 silencing in restoring immune sensitivity.\",\n      \"method\": \"RNAi silencing, pathway inhibitors (FGF2, PKCδ, ERK blockade), apoptosis assays with antigen-specific T cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific pathway phenocopying, multiple inhibitors targeting the same pathway, single lab\",\n      \"pmids\": [\"24769442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FGF2 regulates cytoglobin (CYGB) gene expression and deactivation of myofibroblastic hepatic stellate cells (HSCs) via JNK signaling. FGF2 triggered rapid phosphorylation of JNK and c-JUN; chromatin immunoprecipitation showed phospho-c-JUN binds to the CYGB promoter at -218 to -222 bases from the transcription initiation site. JNK inhibition and c-JUN siRNA abrogated FGF2-mediated CYGB induction.\",\n      \"method\": \"Western blot (JNK/c-JUN phosphorylation), ChIP assay (phospho-c-JUN at CYGB promoter), siRNA knockdown, JNK inhibitor, in vivo bile duct ligation model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — ChIP identifying specific promoter binding site plus siRNA knockdown plus pharmacological inhibition plus in vivo validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28916723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Protein kinase C-delta (PKCδ) physically interacts with connexin43 (Cx43) during FGF2 signaling in osteoblasts. PKCδ preferentially co-precipitates phosphorylated Cx43, and pull-down assays demonstrated that PKCδ associates with the C-terminal tail of Cx43. Cx43 serves as a direct docking platform for PKCδ recruitment to affect FGF2 signaling.\",\n      \"method\": \"Co-immunoprecipitation, pull-down assay with Cx43 C-terminal tail, immunofluorescent co-detection\",\n      \"journal\": \"BMC biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and pull-down confirming physical interaction, localization confirmed by immunofluorescence, single lab\",\n      \"pmids\": [\"20338032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FGF2-induced ERK signaling dynamics in PC12 cells emerge through an intracellular feedback mechanism combined with competition of FGF2 binding to FGFRs and heparan sulfate proteoglycan (HSPG) co-receptors. This competition produces a distinct population-level distribution of transient/sustained ERK signaling states, revealed by temporally controlled microfluidic growth factor perturbations and Bayesian parameter inference.\",\n      \"method\": \"Microfluidics-based temporal perturbation, live-cell ERK biosensor imaging, Bayesian parameter inference/model selection\",\n      \"journal\": \"Molecular systems biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative temporal perturbations with live-cell imaging and computational model selection; mechanistic model of FGFR/HSPG competition confirmed, single lab\",\n      \"pmids\": [\"31777174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FGF2 induces G1 cell cycle arrest in RCS chondrocytes through a Ras/ERK pathway-dependent mechanism. FGF2 activated PLCγ, PKB, ERK, and p38 MAPK. Chemical inhibition of FGFR3 or MEK1/2 antagonized FGF2-mediated growth arrest. Dominant-negative Ras partially reversed growth inhibition. At the molecular level, FGF2-induced arrest involved disintegration of cyclin D3-cdk6 complex and increased association of p21(WAF1) and p27(Kip1) with cyclin-cdk2 and cyclin-cdk4 complexes, inhibiting their kinase activities and leading to underphosphorylation of p107 and p130.\",\n      \"method\": \"Chemical inhibitors (FGFR3, MEK), dominant-negative Ras expression, cell cycle analysis, kinase complex immunoprecipitation, kinase activity assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple loss-of-function approaches and biochemical characterization of cyclin-CDK complexes, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15194433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FGF2 activates TRPC channels in satellite cells, leading to increased intracellular calcium ([Ca2+]i). This calcium elevation induces nuclear translocation of NFATc3 and NFATc2, and increases the number of MyoD-positive cells. These effects were antagonized by the TRPC channel blocker SKF 96365, identifying a pathway: FGF2 → TRPC → [Ca2+]i elevation → NFAT nuclear translocation → MyoD expression/satellite cell activation.\",\n      \"method\": \"Immunostaining, live-cell calcium imaging with X-rhod-1 dye, TRPC blocker (SKF 96365), nuclear translocation imaging, MyoD counting\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct calcium imaging in satellite cells on fibers, pharmacological inhibition at multiple pathway steps, multiple readouts, single lab\",\n      \"pmids\": [\"24575047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Translocated intracellular FGF2 (endocytosed from outside the cell) protects cells against apoptosis independently of FGFR activation and downstream signaling. This anti-apoptotic activity was abolished by inhibitors of FGF2 translocation from endosomes to the cell interior, but not by potent FGFR kinase inhibitors or kinase-dead FGFR1 mutants.\",\n      \"method\": \"FGFR inhibitor treatment, kinase-dead FGFR1 mutant expression, endosomal translocation inhibitors, apoptosis assays (serum starvation/staurosporine models)\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic separation of FGFR-dependent vs. translocation-dependent activities using multiple orthogonal inhibitors, single lab\",\n      \"pmids\": [\"30099027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FGF2 stimulates SDF-1 expression in Sertoli cells via FGFR4-dependent upregulation of Erm transcription factor. Erm knockdown by siRNA decreased Sdf-1 levels. EMSA revealed ERM directly binds to a specific Ets binding site (-846 to -851 nt region) in the Sdf-1 promoter. FGFR4, expressed in TM4 Sertoli cells but not ST2 stromal cells, mediates the differential FGF2 response.\",\n      \"method\": \"siRNA knockdown, FGFR subtype analysis, FGFR blocking experiments, EMSA, Sdf-1 promoter activity assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA identifying specific DNA-binding site, siRNA knockdown, FGFR subtype specificity demonstrated, single lab with multiple methods\",\n      \"pmids\": [\"19301256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HoxA10 directly transcriptionally activates the FGF2 gene in myeloid cells via two cis-elements in the proximal FGF2 promoter. HoxA10-driven FGF2 production induces a PI3K-dependent increase in β-catenin, causing autocrine stimulation of myeloid progenitor proliferation.\",\n      \"method\": \"Promoter reporter assays with cis-element identification, ChIP-type analysis, FGF2 ELISA, PI3K inhibitor, β-catenin western blotting, proliferation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cis-element identification in FGF2 promoter with functional pathway analysis, single lab with multiple methods\",\n      \"pmids\": [\"22493287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"YY1 lactylation at lysine 183 (K183), regulated by p300 acetyltransferase, directly enhances FGF2 transcription in microglia under hypoxia, promoting retinal neovascularization. YY1 K183 mutation eliminated the enhanced FGF2 transcription and angiogenic effects. p300 inhibitor A485 suppressed vascularization in vivo and in vitro.\",\n      \"method\": \"Lactylation site identification by mass spectrometry, site-directed mutagenesis (K183), p300 overexpression/inhibition (A485), FGF2 promoter activity assays, in vivo OIR model\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis of specific lactylation site with functional transcription readout, pharmacological validation in vivo, single lab\",\n      \"pmids\": [\"37085894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ONECUT2 directly binds the FGF2 promoter and transcriptionally upregulates FGF2 expression in HCC. FGF2 in turn upregulates ONECUT2 through the FGFR1/ERK/ELK1 pathway, forming a positive feedback loop. FGF2 knockdown inhibited ONECUT2-mediated HCC metastasis.\",\n      \"method\": \"ChIP assay (ONECUT2 binding FGF2 promoter), siRNA/shRNA knockdown, FGFR1 inhibitor (PD173074), ERK pathway analysis, metastasis assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct promoter binding, pharmacological pathway inhibition, loss-of-function with metastasis phenotype, single lab\",\n      \"pmids\": [\"34839358\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FGF2 mutants with substitutions at Lys-119/Arg-120 and Lys-125 (K119E/R120E and K125E) in the predicted integrin αvβ3 binding interface show reduced integrin binding and are defective in ERK1/2 activation and DNA synthesis. These integrin-binding defective FGF2 mutants act as dominant-negative antagonists, suppressing FGF2 signaling, tube formation, aortic ring sprouting, and in vivo angiogenesis.\",\n      \"method\": \"Integrin binding assays, site-directed mutagenesis, ERK1/2 phosphorylation assays, DNA synthesis assay, tube formation, aortic ring assay, in vivo angiogenesis\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis identifying integrin-binding interface residues with functional validation in vitro and in vivo, single lab with multiple orthogonal assays\",\n      \"pmids\": [\"28302677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FGF2 inhibits thermogenesis in brown and beige adipocytes via autocrine/paracrine mechanisms. Exogenous FGF2 suppresses PGC-1α and PPARγ expression, leading to UCP1 suppression in brown and beige adipocytes. Co-IP experiments and ChIP assays were used to elucidate the mechanism. FGF2-KO mice show enhanced UCP1 expression and thermogenic capacity.\",\n      \"method\": \"FGF2-KO mice, Co-IP, ChIP, luciferase reporter assay, FGF2 supplementation in vitro, FGFR inhibitor, PPARγ agonist, PGC-1α lentivirus\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO combined with in vitro mechanistic dissection using Co-IP, ChIP, and luciferase assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"34710640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FGF-2 signaling in nasopharyngeal carcinoma promotes pericyte-specific expression of CXCL14 via FGFR1/AHR signaling. Pericyte-derived CXCL14 recruits macrophages and promotes their polarization toward an M2-like phenotype. Genetic knockdown of FGF2 or pericyte depletion blocked CXCL14 expression and tumor-associated macrophage infiltration.\",\n      \"method\": \"Gain- and loss-of-function (FGF2 knockdown, pericyte depletion), FGFR1/AHR pathway analysis, xenograft mouse models\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown and cell-type depletion with in vivo validation, pathway mechanistically defined, single lab\",\n      \"pmids\": [\"35439170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FGF2-induced tanycyte proliferation requires connexin 43 (Cx43) hemichannel opening and subsequent purinergic signaling. FGF2 exposure opens tanycytic Cx43 hemichannels, enabling ATP release to the extracellular milieu. Extracellular ATP activates P2Y1 receptors to drive cell division. In vivo continuous infusion of FGF2 with a Cx43 HC inhibitor into the third ventricle blocked β-tanycyte proliferation.\",\n      \"method\": \"BrdU incorporation, Cx43 HC inhibitors (in vitro and in vivo), P2Y1 receptor inhibitors, ATP release measurement, ICV infusion in rats\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition at multiple pathway steps in vitro and in vivo, BrdU functional readout, single lab\",\n      \"pmids\": [\"32936929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"YAP is translocated to the nucleus after radiation in glioma cells, where it promotes FGF2 expression and secretion. Secreted FGF2 then activates the MAPK-ERK pathway to promote DNA damage repair and radioresistance. FGF2 was identified as a novel direct transcriptional target gene of YAP.\",\n      \"method\": \"YAP nuclear translocation imaging, FGF2 promoter ChIP/reporter assays, pharmacological inhibition of YAP-FGF2-MAPK axis, intracranial xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — nuclear translocation documented, direct transcriptional target relationship established, signaling pathway validated with inhibitors in vitro and in vivo, single lab\",\n      \"pmids\": [\"34127812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Endogenous FGF-2 is required for parathyroid hormone (PTH) anabolic effects on osteoblasts. PTH increased Runx-2 protein expression and nuclear accumulation, and phospho-CREB levels in Fgf2+/+ but not Fgf2-/- osteoblasts. FGF-2 silencing in Fgf2+/+ osteoblasts blocked PTH-stimulated Runx-2 and CREB phosphorylation. PTH increased cyclinD1-cdk4/6 in Fgf2+/+ but not Fgf2-/- osteoblasts.\",\n      \"method\": \"Fgf2-/- and Fgf2+/+ osteoblasts, FGF-2 siRNA silencing, Western blot for Runx-2/p-CREB/cyclin-CDK complexes, immunocytochemistry\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout and siRNA silencing with multiple downstream signaling readouts, single lab\",\n      \"pmids\": [\"19107841\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FGF2 exists as multiple isoforms: an 18-kDa secreted form that signals through cell-surface FGFR tyrosine kinases (activating Ras/MAPK/ERK, PI3K, PLCγ, STAT3, and JNK pathways) and high molecular weight nuclear isoforms that act independently of FGFRs; the 18-kDa form is secreted by an unconventional, ER/Golgi-independent mechanism requiring PI(4,5)P2-driven oligomerization and membrane pore formation at the plasma membrane (enhanced by cholesterol-mediated PI(4,5)P2 clustering), with heparan sulfate proteoglycans capturing FGF2 extracellularly; intracellularly, translocated FGF2 exerts FGFR-independent anti-apoptotic activity, and nuclear FGF2 complexes with API5 to regulate mRNA export; FGF2 signaling controls diverse processes including osteoblast differentiation (via ERK-dependent Runx2 phosphorylation at Ser-301 and TAZ induction), satellite cell activation (via TRPC-Ca2+-NFAT), HSC deactivation (via JNK/c-JUN-dependent CYGB transcription), tanycyte proliferation (via Cx43 hemichannel/purinergic axis), and tumor angiogenesis (via STAT3 and reciprocal PDGFR/FGFR upregulation); its activity is modulated by extracellular interactors including heparan sulfate proteoglycans, heparanase, CCN2, PLAP-1/Asporin, and VEGF-B (which inhibits FGF2/FGFR1 signaling by inducing FGFR1/VEGFR1 complex formation).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FGF2 is a multifunctional growth factor that exists as a secreted 18-kDa isoform signaling through cell-surface FGFR tyrosine kinases and high molecular weight nuclear isoforms that act independently of FGFRs [#3]. The 18-kDa form reaches the extracellular space through an unconventional, ER/Golgi-independent route: it is recruited to the inner plasma membrane leaflet by PI(4,5)P2, oligomerizes (predominantly as dimers) into membrane-pore translocation intermediates directly visualized in real time, and is captured at the outer leaflet by heparan sulfates [#1]; cholesterol promotes this secretion by clustering PI(4,5)P2 and raising membrane tension to favor pore formation [#2]. Once engaged with FGFRs and heparan-sulfate co-receptors, FGF2 drives ERK/MAPK, PI3K, PLCγ, STAT3, and JNK outputs whose kinetics are shaped by competition between FGFR and heparan sulfate proteoglycan binding [#19, #20]. Through ERK, FGF2 governs osteoblast differentiation by phosphorylating Runx2 at Ser-301 to stabilize it and by inducing TAZ to promote TAZ-Runx2 transcription [#7, #8], and endogenous FGF2 is required for the PTH anabolic response in osteoblasts [#32]; through other branches it controls satellite-cell activation via a TRPC-Ca2+-NFAT-MyoD axis [#21], deactivates hepatic stellate cells by driving JNK/c-JUN-dependent CYGB transcription [#17], and stimulates tanycyte proliferation via Cx43 hemichannel ATP release and purinergic P2Y1 signaling [#30]. FGF2 is a central driver of pathologic angiogenesis and tumor progression, acting through STAT3, reciprocal PDGFR/FGFR cross-induction, and an integrin αvβ3-binding interface required for ERK activation and neovascularization [#9, #10, #27]. Nuclear FGF2 complexes with API5 through a cryptic nuclear localization sequence to regulate mRNA export via the TREX and eIF4E/LRPPRC pathways [#0], and intracellularly translocated FGF2 exerts FGFR-independent anti-apoptotic activity [#22]. Its activity is tuned by extracellular interactors including heparanase-remodeled heparan sulfate [#14], CCN2 [#11], PLAP-1/Asporin [#12], and VEGF-B, which inhibits FGF2/FGFR1 signaling by inducing FGFR1/VEGFR1 complexes [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established that FGF2 can act as a growth-arrest signal rather than only a mitogen, defining how it imposes G1 arrest through Ras/ERK in chondrocytes.\",\n      \"evidence\": \"Chemical inhibitors, dominant-negative Ras, and cyclin-CDK complex analysis in RCS chondrocytes\",\n      \"pmids\": [\"15194433\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type basis for arrest versus proliferation outputs not resolved\", \"Did not address nuclear FGF2 isoform contributions\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved how FGF2-ERK signaling is converted into osteoblast differentiation by identifying Runx2 Ser-301 as the ERK phosphorylation site controlling Runx2 stability.\",\n      \"evidence\": \"Site-directed mutagenesis, constitutively active MEK, and ERK inhibition with biochemical readouts\",\n      \"pmids\": [\"20007706\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase-substrate directness in vivo not shown\", \"Other ERK substrates in osteogenesis not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Distinguished FGFR-independent nuclear HMW FGF2 isoforms from the FGFR-signaling 18-kDa form, framing FGF2 as a dual intracellular/extracellular factor.\",\n      \"evidence\": \"Review synthesizing cell fractionation, isoform expression, and nuclear localization studies\",\n      \"pmids\": [\"18850066\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism of HMW nuclear function unspecified\", \"Trafficking determinants not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed endogenous FGF2 is necessary for the PTH anabolic program, placing FGF2 as a required cofactor in hormone-driven osteoblast signaling.\",\n      \"evidence\": \"Fgf2-/- versus Fgf2+/+ osteoblasts plus siRNA silencing with Runx2/CREB/cyclin-CDK readouts\",\n      \"pmids\": [\"19107841\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether intracrine or autocrine FGF2 mediates the requirement unresolved\", \"Receptor subtype not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Added a transcriptional arm to FGF2-driven osteogenesis by showing ERK-induced TAZ enables TAZ-Runx2 cooperation.\",\n      \"evidence\": \"shRNA knockdown, ERK inhibition, nuclear fractionation, and TAZ-Runx2 Co-IP\",\n      \"pmids\": [\"24125755\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking ERK to TAZ induction not detailed\", \"Single cell-system validation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined distinct effector branches downstream of FGF2 in non-bone tissues — TRPC-Ca2+-NFAT for satellite cell activation.\",\n      \"evidence\": \"Calcium imaging, TRPC blocker, and NFAT/MyoD readouts in satellite cells\",\n      \"pmids\": [\"24575047\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"FGFR subtype coupling TRPC not identified\", \"Direct channel activation mechanism not shown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified a JNK/c-JUN transcriptional output through which FGF2 deactivates myofibroblastic hepatic stellate cells by driving CYGB.\",\n      \"evidence\": \"ChIP localizing phospho-c-JUN to the CYGB promoter, siRNA, JNK inhibition, and in vivo bile duct ligation\",\n      \"pmids\": [\"28916723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream coupling from FGFR to JNK not mapped\", \"Reversibility of HSC deactivation not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Mapped an integrin αvβ3-binding interface on FGF2 required for ERK activation and angiogenesis, yielding dominant-negative antagonist mutants.\",\n      \"evidence\": \"Site-directed mutagenesis at Lys-119/Arg-120 and Lys-125 with binding, signaling, and in vivo angiogenesis assays\",\n      \"pmids\": [\"28302677\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural integrin-FGF2 complex not determined\", \"Relationship to FGFR engagement not fully separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided the structural basis for nuclear FGF2 by solving the API5-FGF2 complex and identifying a cryptic NLS, linking nuclear FGF2 to mRNA export.\",\n      \"evidence\": \"X-ray crystallography, Co-IP, and mRNA export functional assays implicating TREX and eIF4E/LRPPRC\",\n      \"pmids\": [\"32383752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological role of API5-FGF2 mRNA export unclear\", \"Isoform specificity of nuclear import not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Directly visualized the unconventional secretion mechanism, showing FGF2 oligomerizes and forms membrane-pore translocation intermediates at the plasma membrane.\",\n      \"evidence\": \"Live-cell TIRF microscopy with dual-channel imaging and oligomer detection establishing PI(4,5)P2 and heparan sulfate dependence\",\n      \"pmids\": [\"30470711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pore stoichiometry and resealing dynamics not fully defined\", \"In vivo relevance of measured kinetics unaddressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Separated FGFR-independent intracellular function of FGF2 by showing translocated FGF2 protects against apoptosis independent of receptor kinase activity.\",\n      \"evidence\": \"FGFR kinase inhibitors, kinase-dead FGFR1, and endosomal translocation inhibitors in apoptosis assays\",\n      \"pmids\": [\"30099027\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Intracellular anti-apoptotic effector(s) unidentified\", \"Mechanism of endosome-to-cytosol translocation incomplete\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Quantitatively explained variability in FGF2-ERK signaling as a consequence of FGFR/HSPG co-receptor competition with intracellular feedback.\",\n      \"evidence\": \"Microfluidic temporal perturbations, live-cell ERK biosensors, and Bayesian model selection in PC12 cells\",\n      \"pmids\": [\"31777174\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular identity of the intracellular feedback node not specified\", \"Generalizability beyond PC12 cells untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Explained how membrane lipid composition gates FGF2 secretion, showing cholesterol clusters PI(4,5)P2 to promote oligomerization and pore formation.\",\n      \"evidence\": \"Live-cell imaging, atomistic MD simulations, and membrane tension/binding assays\",\n      \"pmids\": [\"36173379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological regulation of cholesterol-driven secretion in vivo not shown\", \"Quantitative contribution relative to PI(4,5)P2 alone not parsed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified VEGF-B as an endogenous inhibitor of FGF2/FGFR1 signaling acting by inducing FGFR1/VEGFR1 receptor complexes.\",\n      \"evidence\": \"Binding assays, receptor Co-IP, ERK phosphorylation, and in vitro/in vivo angiogenesis models\",\n      \"pmids\": [\"37591843\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of the FGFR1/VEGFR1 complex not resolved\", \"Context-dependence on FGFR1 abundance needs broader validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the FGFR-dependent surface signaling, FGFR-independent intracellular protection, and nuclear mRNA-export functions of FGF2 are coordinated within a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated model linking isoform partitioning to functional output\", \"Quantitative balance between unconventional secretion and intracrine retention unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 9, 10, 13]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 19, 20]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 3, 5]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 17, 19, 20]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 10, 15, 26, 31]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"complexes\": [\n      \"FGF2-API5 nuclear complex\",\n      \"FGF2-FGFR1 receptor complex\"\n    ],\n    \"partners\": [\n      \"FGFR1\",\n      \"API5\",\n      \"CCN2\",\n      \"PLAP-1/ASPN\",\n      \"VEGFB\",\n      \"heparan sulfate proteoglycan\",\n      \"integrin alphavbeta3\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}